Neo Ivy Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Neo Ivy Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-24,720	Closed	-$1.08M	–	485
2023 Q3	$1.08M	Buy	+24,720	New	+$883K	0.47%	74
2022 Q4	$85K	Buy	+1,866	New	+$121K	0.06%	266
2022 Q2	–	Sell	-3,612	Closed	-$296K	–	661
2022 Q1	$296K	Buy	+3,612	New	+$369K	0.27%	141
2020 Q4	–	Sell	-562	Closed	-$93K	–	616
2020 Q3	$93K	Buy	+562	New	+$76.9K	0.09%	298
2019 Q3	–	Sell	-8,554	Closed	-$881K	–	418
2019 Q2	$881K	Buy	+8,554	New	+$666K	0.5%	84

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Neo Ivy Capital Management's MRTX Position: Q4 2023 in Review

Neo Ivy Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 24,720 shares — an estimated $1.08M sold.

Neo Ivy Capital Management first reported a position in MRTX in Q2 2019 and held it in 5 quarters. The position peaked at $1.08M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Neo Ivy Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Neo Ivy Capital Management sold 24,720 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.08M.
Neo Ivy Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
Neo Ivy Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $1.08M in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Neo Ivy Capital Management's 13F filing for Q4 2023, filed 26 Feb 2024.